Actinogen Medical Limited (ASX:ACW) shareholders might be rather concerned because the share price has dropped 47% in the last month. But that doesn't undermine the fantastic longer term ...

Against this backdrop, The Bloomberg U.S. Aggregate Bond Index generated a modest gain (+0.07%) un Q2. After raising policy rates 11 times beginning in March 2022, the U.S. central bank has since held ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Nowadays, the industry is seeing rates decline. With this backdrop, companies are increasingly moving towards digital solutions for efficiency gains, allowing people to handle more integrated tasks, ...

Ongoing development of Xanamem, a unique inhibitor of the 11B-HSD1 enzyme that achieves target engagement in the central nervous system.

Actinogen Medical (ASX:ACW)’s stock price more than doubled this morning after announcing promising results from its XanCIDD phase 2a trial. The latest data shows that ACW’s lead drug, Xanamem, has ...